Warning
Breckenridge Pharmaceutical Recalls Duloxetine Delayed-Release Capsules USP
This is a Class II recall. This product may cause temporary health problems or pose a slight threat of a serious nature.
Source: FDA
WarningRecall #D-0522-2026Drug / Pharmaceutical
Breckenridge Pharmaceutical Recalls Duloxetine Delayed-Release Capsules USP
Breckenridge Pharmaceutical, Inc. · Class II — Moderate Risk
Product Description
Duloxetine Delayed-Release Capsules USP, 60mg, Rx Only, 90-count bottle, Mfr. by Towa Pharmaceutical Eurpoe S.L., Martorelles, (Barcelona), Spain, Dist. by. Breckenridge Pharmaceutical, Inc., Berkely Heights, NJ 07922, NDC 51991-748-90.
Reason for Recall
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
FDA Classification
Class II — Moderate Risk
A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Distribution
Nationwide in the USA
Remedy
Consumers should stop using this product. Contact the recalling firm for further instructions regarding this product.
411 Press Analysis
Breckenridge Pharmaceutical, Inc. has recalled a pharmaceutical product that the FDA classified as Class II affecting 165,761 90-count bottles. The recall was initiated on April 21, 2026. CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit. It was distributed nationwide. Class II recalls involve products that might cause a temporary health problem or pose only a slight threat of a serious nature. Consumers should discontinue use and contact the firm.
Sources: FDA openFDA Enforcement Database
This recall appears in: Drug & Medical Product Contamination.